HELIOS Klinikum Bad Saarow

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Liver and biliary tract cancer6 trials
• Sarcoma5 trials
• Gastric and oesophageal cancer4 trials
• Colorectal cancer3 trials
• Acute myeloid leukaemia2 trials
• Pancreatic cancer2 trials
• Acute lymphoblastic leukaemia1 trial
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Myeloproliferative neoplasms1 trial

Phase

• Phase 28 trials
• Phase 35 trials
• Phase 2/32 trials
• Phase 1/21 trial

Status

• Completed11 trials
• Recruiting5 trials
• Active, not recruiting4 trials
• Terminated2 trials
• Not yet recruiting1 trial

Lead sponsor

• Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest14 trials
• University of Ulm3 trials
• Boehringer Ingelheim1 trial
• Eli Lilly and Company1 trial
• German CLL Study Group1 trial
• and 3 more

Running trials

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

  Contact: Tobias Klatte (principal investigator)

• Recruiting

  - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

  NCT06856837· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

  Contact: Daniel Pink, MD

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· PharmaMar· Source

• Active, not recruiting

  Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

  NCT05174650· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Recruiting

  A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

  NCT05197192· Phase 3· German CLL Study Group· Source

  Contact: Daniel Schöndube

• Active, not recruiting

  Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

  NCT03897127· Phase 3· University of Ulm· Source

• Recruiting

  GISAR German Interdisciplinary Sarcoma Registry

  NCT04122872· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

  Contact: Daniel Pink, Dr. med.

• Active, not recruiting

  Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT02227251· Phase 2· Karyopharm Therapeutics Inc· Source

• Recruiting

  Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project

  NCT01252485· University of Ulm· Source

  Contact: Daniel Schöndube, Dr.med.

• Recruiting

  GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

  NCT02872987· Goethe University· Source

  Contact: Nicola Gökbuget, Dr. med.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Terminated

  Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients

  NCT06050434· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

  NCT04896931· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

  NCT05080790· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

  NCT04511455· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

  NCT04484636· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Terminated

  The PLATON Network

  NCT05489250· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

  NCT04522908· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

  NCT03520946· Phase 3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

  NCT03647969· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

  NCT03530267· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

  NCT03081143· Phase 2/3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

  NCT01644110· Phase 1/2· University of Ulm· Source